Published in J Pharmacol Exp Ther on April 01, 1991
Antioxidant therapy against cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cell Mol Neurobiol (1999) 0.81
Comparison of the involvement of protein kinase C in agonist-induced contractions in mouse aorta and corpus cavernosum. Eur J Pharmacol (2008) 0.81
Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system. Mol Cell Biochem (1996) 0.80
The role of diacylglycerol and activation of protein kinase C in alpha 1A-adrenoceptor-mediated contraction to noradrenaline of rat isolated epididymal vas deferens. Br J Pharmacol (1996) 0.78
Evidence for L-glutamate as the neurotransmitter of baroreceptor afferent nerve fibers. Science (1980) 1.29
Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res (1992) 1.28
Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol (1988) 1.25
Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol (1991) 1.20
Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol (1993) 1.17
Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: involvement of potassium channels. J Pharmacol Exp Ther (1992) 1.17
RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther (1997) 1.03
The pain resource nurse training program: a unique approach to pain management. J Pain Symptom Manage (1993) 1.01
Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther (1998) 1.00
Unscheduled readmissions for uncontrolled symptoms. A health care challenge for nurses. Nurs Clin North Am (1995) 0.92
Postnatal persistence of capillary-venous differences in hematocrit and hemoglobin values in low-birth-weight and term infants. Pediatrics (1982) 0.92
Acute hypertension after the local injection of kainic acid into the nucleus tractus solitarii of rats. Circ Res (1981) 0.91
Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864. Biochem Biophys Res Commun (1993) 0.90
Regulation of pituitary receptors for thyrotropin-releasing hormone by thyroid hormones. J Biol Chem (1978) 0.89
Improving cancer pain management using a performance improvement framework. J Nurs Care Qual (1999) 0.89
Pharmacological analysis of alpha-2 adrenergic mechanisms in nociception and ataxia. J Pharmacol Exp Ther (1985) 0.88
Evidence that glutamic acid is the neurotransmitter of baroreceptor afferent terminating in the nucleus tractus solitarius (NTS). J Auton Nerv Syst (1981) 0.88
Biochemical evidence that L-glutamate is a neurotransmitter of primary vagal afferent nerve fibers. Brain Res (1981) 0.86
Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. Eur J Pharmacol (1990) 0.84
Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol (1997) 0.84
In vitro and in vivo characterization of an A1-selective adenosine agonist, RG14202. J Pharmacol Exp Ther (1993) 0.84
Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther (1989) 0.83
Relationships between thyroid hormone and glucocorticoid effects in GH3 pituitary cells. Endocrinology (1980) 0.83
Phorbol-12,13-dibutyrate-induced vasoconstriction in vivo: characterization of response in genetic hypertension. J Pharmacol Exp Ther (1990) 0.83
Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. J Cardiovasc Pharmacol (1999) 0.82
Respiratory rate greater than 50 per minute as a clinical indicator of pneumonia in Filipino children with cough. Rev Infect Dis (1991) 0.82
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines. J Med Chem (1987) 0.82
In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur J Pharmacol (1992) 0.82
Differential alteration of vascular reactivity in rabbit aorta with modest elevation of serum cholesterol. Circ Res (1990) 0.81
Episodic laryngeal dyskinesia. Clinical and psychiatric characterization. Chest (1986) 0.81
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. Thromb Haemost (1997) 0.81
Diagnostic value of fasting plasma peptide concentrations in patients with chronic diarrhea. Dig Dis Sci (1994) 0.81
Identification and characterization of substance P receptors on LRM55 glial cells. J Pharmacol Exp Ther (1986) 0.81
1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung (1996) 0.80
Antagonism of the baroreceptor reflex by glutamate diethyl ester, an antagonist to L-glutamate. Brain Res (1981) 0.80
Binding of [3H]substance P to putative substance P receptors in rat brain membranes. Eur J Pharmacol (1983) 0.80
RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.79
Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol (1998) 0.79
Thyroid hormone action in pituitary cells. Differences in the regulation of thyrotropin-releasing hormone receptors and growth hormone synthesis. J Biol Chem (1979) 0.79
Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs. Thromb Res (2001) 0.79
Cancer pain education for patients. Semin Oncol Nurs (1997) 0.79
Mechanism of thyroid hormone inhibition of thyrotropin-releasing hormone action. Endocrinology (1981) 0.79
Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa. J Cardiovasc Pharmacol (1999) 0.78
Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization. J Med Chem (1999) 0.78
Characterization and inhibition of 15-lipoxygenase in human monocytes: comparison with soybean 15-lipoxygenase. Am J Physiol (1995) 0.78
Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats. J Cardiovasc Pharmacol (1997) 0.78
Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J Med Chem (1998) 0.78
Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation. Hypertension (1993) 0.77
Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol (2001) 0.77
In vitro characterization of a novel factor Xa inhibitor, RPR 130737. Thromb Res (2000) 0.77
Electrode cuff-induced changes in DNA and PDGF gene expression in the rat carotid artery. Atherosclerosis (1993) 0.77
Anorexia, cachexia, and dysphagia: the symptom experience. Semin Oncol Nurs (1995) 0.76
Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem (1999) 0.76
Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res (2001) 0.76
Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology (1995) 0.76
RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit. Thromb Haemost (1999) 0.75
Does tumor necrosis factor-alpha (TNF-alpha) contribute to myocardial reperfusion injury in anesthetized rats? Gen Pharmacol (1999) 0.75
Ischaemia/reperfusion selectively attenuates coronary vasodilatation to an adenosine A2- but not to an A1-agonist in the dog. Br J Pharmacol (1994) 0.75
The role of the neutrophil and formed elements of the blood in an in vitro model of reperfusion injury. Mediators Inflamm (1993) 0.75
Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs. J Cardiovasc Pharmacol (2001) 0.75
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives. J Med Chem (1987) 0.75
Timely discharge for the patient undergoing outpatient surgery. Oncol Nurs Forum (1995) 0.75
Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist. Thromb Res (1996) 0.75
Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa. Bioorg Med Chem Lett (2000) 0.75
RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology (1993) 0.75
Ethical decision making in oncology: a case study approach. Cancer Pract (1995) 0.75
Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors. Bioorg Med Chem Lett (1999) 0.75
Pharmacology of RG W-2938: a cardiotonic agent with vasodilator activity. J Cardiovasc Pharmacol (1990) 0.75
Lovastatin is hypertriglyceridemic in Syrian golden hamsters. Biochem Biophys Res Commun (1988) 0.75